- Blackstone closed its largest life science fund, raising $6.3B for BXLS VI.
- The fund was oversubscribed and is nearly 40% larger than its predecessor.
- BXLS VI is now the biggest private life science fund on record.
- Blackstone’s life science platform has achieved 34 regulatory approvals since 2018.
Fundraising Milestone for Life Science Leaders
According to Globe St, Blackstone continues to expand its presence in life sciences, recently closing BXLS VI with $6.3B in commitments. Notably, the oversubscribed fund reached its hard cap and outpaces the prior fund in the series by almost 40%. As a result, the record-breaking raise confirms heightened investor demand in the life science fund sector.
Investor Momentum Builds
Since launching the BXLS platform in 2018, Blackstone has made significant investments in new medicines and medical technologies. For example, notable products funded include AMVUTTRA®, IMBRUVICA, LEQVIO, and the MiniMed Flex technology device. More recently, nearly $2B has been deployed by the BXLS platform over the past year. Importantly, the approval rate for Blackstone-backed Phase III products stands at 86%, well above averages in the life sciences field.
Get Smarter about what matters in CRE
Stay ahead of trends in commercial real estate with CRE Daily – the free newsletter delivering everything you need to start your day in just 5-minutes
Why It Matters
BXLS VI’s close highlights growing global conviction in life sciences as a commercial real estate and investment sector. Blackstone’s success reflects its strong partnerships with biopharma and device innovators, yielding 34 regulatory approvals to date. At the same time, institutional capital continues to flow into alternative asset classes tied to innovation and stability, reinforcing life sciences’ position among the most sought-after strategies. The firm’s $15B life science AUM includes support from major institutional investors worldwide.
What’s Next
While specific deployment plans for BXLS VI weren’t disclosed, Blackstone remains active across both life sciences and broader CRE markets. Recent notable property dispositions include the $730M sale of Park Avenue Tower and other major assets, showing ongoing CRE portfolio management alongside life science growth.
